Loading…
Health Catalyst, Inc. is projected to rise to $2.67 by 2027, a +28% move from its current price of $2.09. HCAT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $2.03 | $2.09 | $2.15 | +0.03% |
| Aug 5 | $2.01 | $2.09 | $2.18 | +0.05% |
| Aug 6 | $1.99 | $2.09 | $2.20 | +0.08% |
| Aug 7 | $1.97 | $2.09 | $2.22 | +0.11% |
| Aug 8 | $1.96 | $2.09 | $2.24 | +0.14% |
| Aug 9 | $1.95 | $2.09 | $2.25 | +0.16% |
| Aug 10 | $1.94 | $2.09 | $2.26 | +0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.94 | $2.09 | $2.26 | +0.19% |
| Week 2 | $1.88 | $2.10 | $2.34 | +0.38% |
| Week 3 | $1.84 | $2.10 | $2.41 | +0.57% |
| Week 4 | $1.80 | $2.11 | $2.46 | +0.77% |
| Week 5 | $1.77 | $2.11 | $2.51 | +0.96% |
| Week 6 | $1.74 | $2.11 | $2.56 | +1.15% |
| Week 7 | $1.72 | $2.12 | $2.61 | +1.34% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments: Technology and Professional Services.
It offers Ignite Data and Analytics Platform that provides clients a single comprehensive environment to integrate and organize data from their disparate software systems; and Applications, a software analytics applications build for Ignite platform to analyze clients’ data across clinical improvement, revenue and cost improvement, ambulatory operations, measures and registries, and data and analytics. The company also provides expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. It serves academic medical centers, integrated delivery networks, community hospitals, large physician practices, accountable care organizations, health information exchanges, health insurers, life science organizations, healthcare technology vendors, and other risk-bearing entities.
The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.
Health Catalyst, Inc. trades as HCAT and has a current price of $2.10 with a market capitalization of $155.18M, ranking 3951 by size. The stock sits in a price environment that is supported by a 30-day range of $1.68 to $2.63 and shows a technical setup with a 50-day simple moving average of $1.75 and a 200-day simple moving average of $2.04.
The near-term outlook provides a path of gradual appreciation with notable upside potential reflected in the year-by-year forecast.
A major floor 52.3% below — a decisive break under it would weaken the trend.
The nearest floor, 17.7% below — buyers have tended to step in here.
The nearest ceiling, 11.5% above — a clean break opens room to run.
A major ceiling 27.1% above — clearing it would confirm fresh momentum.
Key HCAT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HCAT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.12 | Sell | $2.11 | Sell |
| MA 10 | $2.10 | Sell | $2.12 | Sell |
| MA 20 | $2.19 | Sell | $2.10 | Sell |
| MA 50 | $1.87 | Buy | $1.93 | Buy |
| MA 100 | $1.58 | Buy | $1.86 | Buy |
| MA 200 | $2.01 | Buy | $2.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.04 | Neutral |
| Stoch RSI (14) | 14.62 | Buy |
| CCI (20) | -75.19 | Neutral |
| Williams %R (14) | -75.00 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -10.30 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 25.00 | Neutral |
| TRIX (15) | 0.67 | Buy |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 52.14 | Neutral |
| Momentum (10) | -0.16 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 2.13 | Sell |
| ADX (14) | 20.13 | Buy |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is neutral, with RSI(14) at 50. The stock trades above both the 50-day SMA ($1.75) and the 200-day SMA ($2.04). The 30-day range is $1.68 to $2.63, and the current price of $2.10 sits within that range. Support is $1.60 and resistance is $2.33, outlining a defined near-term band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.996 | $2.09 | $2.86 | 0% | Neutral | |
| $2.12 | $2.67 | $3.58 | +28% | Bullish | |
| $2.40 | $3.13 | $4.36 | +50% | Bullish | |
| $2.72 | $3.63 | $5.23 | +74% | Bullish | |
| $2.65 | $3.62 | $5.35 | +73% | Bullish | |
| $2.67 | $3.72 | $5.62 | +78% | Bullish | |
| $2.88 | $4.10 | $6.32 | +96% | Bullish | |
| $3.16 | $4.58 | $7.20 | +119% | Bullish | |
| $3.95 | $5.83 | $9.31 | +179% | Bullish | |
| $4.12 | $6.17 | $10.02 | +195% | Bullish | |
| $5.63 | $9.09 | $15.76 | +335% | Bullish | |
| $8.20 | $15.08 | $28.73 | +621% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.996 | $2.09 | $2.60 | +0.00% |
| September 2026 | $1.81 | $2.15 | $2.62 | +2.72% |
| October 2026 | $1.79 | $2.14 | $2.65 | -0.20% |
| November 2026 | $1.86 | $2.24 | $2.79 | +4.49% |
| December 2026 | $1.88 | $2.28 | $2.86 | +1.68% |
Click any year to see its month-by-month HCAT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, HCAT is projected to trade between $0.996 and $2.86, averaging $2.09 — a potential gain of 0% from today's $2.09. A consolidation phase looks the most probable path here.
Health Catalyst, Inc.'s 2027 outlook centres on $2.67, within a $2.12 to $3.58 range. That is up +28% on the projected 2026 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2028, HCAT could reach as high as $4.36, with a base case around $3.13 and support toward $2.40 — roughly +50% from $2.09. Buyers look set to stay in control over this stretch.
Expect HCAT to range from $2.72 to $5.23 through 2029. The $3.63 average target implies a +74% move from current prices. That is up +16% on the projected 2028 average. Momentum favours further upside here.
The HCAT price prediction for 2030 points to an average of $3.62 (low $2.65, high $5.35) — a potential gain of +73% on today's $2.09. Buyers look set to stay in control over this stretch.
In 2031, HCAT is projected to trade between $2.67 and $5.62, averaging $3.72 — a potential gain of +78% from today's $2.09. That is up +3% on the projected 2030 average. Momentum favours further upside here.
Health Catalyst, Inc.'s 2032 outlook centres on $4.10, within a $2.88 to $6.32 range. That is up +10% on the projected 2031 average. That marks a +96% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, HCAT could reach as high as $7.20, with a base case around $4.58 and support toward $3.16 — roughly +119% from $2.09. Momentum favours further upside here.
Expect HCAT to range from $3.95 to $9.31 through 2034. The $5.83 average target implies a +179% move from current prices. That is up +27% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The HCAT price prediction for 2035 points to an average of $6.17 (low $4.12, high $10.02) — a potential gain of +195% on today's $2.09. Momentum favours further upside here.
In 2040, HCAT is projected to trade between $5.63 and $15.76, averaging $9.09 — a potential gain of +335% from today's $2.09. That is up +47% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Health Catalyst, Inc.'s 2050 outlook centres on $15.08, within a $8.20 to $28.73 range. That is up +66% on the projected 2040 average. That marks a +621% change versus current levels. Momentum favours further upside here.
Investing $1,000 in HCAT today (≈ 478.4689 HCAT) could be worth
$7,213.2
+$6,213.2 (+621%) by 2050 · US Dollar
Based on the average projected HCAT price of $15.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HCATwould be worth at today's price.
$1,000 invested in HCAT on Jul 31, 2025 (≈ 273.972596 HCAT) would be worth
$572.6
-$427.4 (-42.7%) today · 0.57× · US Dollar
Based on a HCAT entry price of $3.65 vs. today's $2.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.08 | $1,004.81 | +0.5% |
| 1 month ago | $2.07 | $1,009.66 | +1.0% |
| 3 months ago | $1.45 | $1,441.38 | +44.1% |
| 6 months ago | $2.3 | $908.7 | -9.1% |
| 1 year ago | $3.65 | $572.6 | -42.7% |
| All time (5.0y) ago | $55.95 | $37.35 | -96.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HCAT forecast.
Our base-case forecast reaches $4.20 around 2033.
Implied market cap at $4.20: $310.35M
The multi-year forecast shows a bullish trajectory, with the average price rising from $2.10 in 2026 to $10.95 by 2050. The year-by-year averages include 2027 at $2.53, 2028 at $2.99, 2029 at $3.38, 2030 at $3.29, 2031 at $3.28, 2032 at $3.44, 2033 at $3.81, 2034 at $4.97, and 2035 at $5.12, followed by higher targets of $7.31 in 2040 and $10.95 in 2050. corresponding ROI figures show a path from 0% in 2026 to 56.7% in 2030, 56.2% in 2031, 63.9% in 2032, 81.5% in 2033, 136.9% in 2034, 144% in 2035, 248.1% in 2040, and 421.6% in 2050.
The sentiment outlook shifts to BULLISH from 2027 onward. These figures are estimates and not guarantees, and they reflect the stated forecast ranges.
Tap a question to reveal the answer.
The forecasted average price in 2030 is $3.29, with a min of $2.33 and a max of $5.03. The ROI is 56.7% and the sentiment is BULLISH.
Forecasts show a bullish sentiment from 2027 onward with rising average prices and ROIs that peak at 421.6% by 2050. Remember, these are estimates and not guarantees.
The 2050 forecast shows an average price of $10.95 and a max of $22.16, indicating potential to reach around $11 on average by 2050, with higher upside possible in the max scenario.
Current price is $2.10 and market cap is $155.18M.
RSI(14) is 50, with SMA(50) at $1.75 and SMA(200) at $2.04. The 30-day range is $1.68 to $2.63, with support at $1.60 and resistance at $2.33.
Health Catalyst, Inc. Community Discussion
0Share your Health Catalyst, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.